The Surem TRAF3IP2 Level and Atherosclerotic Plaque Development in Human
NCT ID: NCT05945394
Last Updated: 2023-09-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
800 participants
OBSERVATIONAL
2023-09-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography
NCT06863545
Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease
NCT01735305
Effect of Atorvastatin and Lifestyle Intervention on Progression of Pre-Clinical Atherosclerosis
NCT00723320
A Study for Exploring the Efficacy of Naoxintong Capsules in the Treatment of Coronary Atherosclerotic Plaque on the Basis of Optimal Medical Therapy (Aspirin,Statins,Clopidogrel, Etc.): Stage One
NCT05278182
Detection of Plaque Inflammation by Positron Emission Tomography (PET)-Effects of Simvastatin on Plaque Inflammation
NCT00114504
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with suspected CHD who experienced CAG
Patients with suspected coronary heart disease who experienced coronary angiography
No intervention
This is an obvertional study, and there is no intervention.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
This is an obvertional study, and there is no intervention.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. patients received coronary angiography
Exclusion Criteria
2. malignant tumor
3. acute infection
4. thyroid dysfunction
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanjing Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jin Geng
associate doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ma Shuren, MD
Role: STUDY_DIRECTOR
NJMU
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huai'an First People's Hospital
Huai'an, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xiaozhong Yang, MD.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20230503
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.